Loading...
•
Sep 30, 2024
Celsion Q3 2024 Earnings Report
IMUNON reported financial results for Q3 2024 and provided business updates.
Key Takeaways
IMUNON reported a net loss of $4.9 million, or $0.34 per share, for the third quarter of 2024. The company had $10.3 million in cash, investments and accrued interest receivable as of September 30, 2024. The company believes it has sufficient capital resources to fund its operations into the third quarter of 2025.
IMUNON is on track to begin its planned 500-patient pivotal Phase 3 study during the first quarter of 2025.
The company presented new OVATION 2 data at the Society for Immunotherapy of Cancer 39th Annual Meeting.
IMUNON raised gross proceeds of $10 million in a registered direct financing.
Susan Eylward was named General Counsel and Corporate Secretary and Kristin Longobardi was named Senior Vice President of Operations.
Forward Guidance
IMUNON believes it has sufficient capital resources to fund its operations into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...